journal article·2022-12

Tumor Microenvironment‐Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade‐Amplified Immune Response against Tumor Growth, Metastasis and Recurrence

Songlin Gong, Xiuqi Liang, Miaomiao Zhang, Lu Li, Tao He, Yuan Yuan, Xinchao Li, Furong Liu, Xi Yang, Meiling Shen, Qinjie Wu, Changyang Gong

Small· Volume 18· Issue 50
Publisher page

Abstract

Abstract In situ tumor vaccines (ITV) have been recognized as a promising antitumor strategy since they contain the entire tumor‐specific antigens, avoiding tumor cells from evading immune surveillance due to antigen loss. However, the therapeutic benefits of ITV are limited by obstacles such as insufficient antigen loading, inadequate immune system activation, and immunosuppressive tumor microenvironments (TME). Herein, a tumor microenvironment‐activated hydrogel platform (TED‐Gel) with programmed drug release property is constructed for cascaded amplification of the anti‐tumor immune response elicited by ITV. Both doxorubicin (Dox) and cytosine‐phosphate‐guanosine oligodeoxynucleotides (CpG) are released first, in which Dox induces immunogenic tumor cell death causing additional tumor antigen release and leading the dying primary tumor cells into autologous tumor vaccine, and the released CpG promotes antigen presenting cell activation. Subsequently, the decomposed scaffold materials in conjunction with CpG, turn the anti‐inflammatory M2‐like macrophages into the M1 type, reversing the immunosuppressive TME. With decomposition of the TED‐Gel, large amounts of macromolecule anti‐PD‐L1 antibodies are liberated, reinvigorating the exhausted effector T cells. In vivo studies demonstrate that TED‐Gel significantly inhibits the primary, distant and rechallenged tumor growth. Overall, the simple and powerful TED‐Gel provides an alternative strategy for the future development of tumor vaccines with broad application.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University Chengdu 610041 P. R. China

Department of Pancreatic Surgery West China Hospital Sichuan University Chengdu 610041 P. R. China

Funding

National Natural Science Foundation of China · Key Research and Development Program of Sichuan Province · West China Hospital, Sichuan University

References (46)

Show source-provided references
1. 10.1002/advs.20180186810.1002/advs.201801868 ↗
2. 10.1016/j.biomaterials.2020.12011410.1016/j.biomaterials.2020.120114 ↗
3. 10.1038/s41467-018-03915-410.1038/s41467-018-03915-4 ↗
4. 10.1038/s41551-020-0599-510.1038/s41551-020-0599-5 ↗
5. 10.1016/j.jconrel.2018.10.00810.1016/j.jconrel.2018.10.008 ↗
6. 10.1002/anie.20180488210.1002/anie.201804882 ↗
7. 10.1002/smll.20200490510.1002/smll.202004905 ↗
8. 10.1038/s41418-020-00658-y10.1038/s41418-020-00658-y ↗
9. 10.1038/nrc338010.1038/nrc3380 ↗
10. 10.1038/cdd.2013.8410.1038/cdd.2013.84 ↗
11. 10.1002/smll.20200490510.1002/smll.202004905 ↗
12. 10.1021/acsnano.5b0201410.1021/acsnano.5b02014 ↗
13. 10.1038/s41467-020-15129-810.1038/s41467-020-15129-8 ↗
14. 10.1038/8528610.1038/85286 ↗
15. 10.1002/adma.20200791010.1002/adma.202007910 ↗
16. 10.1084/jem.2005091510.1084/jem.20050915 ↗
17. 10.7150/thno.5817310.7150/thno.58173 ↗
18. 10.1002/adhm.20200208010.1002/adhm.202002080 ↗
19. 10.1016/j.biomaterials.2020.12021810.1016/j.biomaterials.2020.120218 ↗
20. 10.3390/cancers1205118110.3390/cancers12051181 ↗
21. 10.1073/pnas.080978410610.1073/pnas.0809784106 ↗
22. Dalen F. J. · Molecules · 2018 · 24 · 10009
23. 10.4049/jimmunol.164.12.616610.4049/jimmunol.164.12.6166 ↗
24. 10.1016/j.coi.2011.12.00910.1016/j.coi.2011.12.009 ↗
25. 10.1002/smll.20180240310.1002/smll.201802403 ↗
26. 10.1126/sciadv.abb311610.1126/sciadv.abb3116 ↗
27. 10.1016/j.jtho.2017.04.01410.1016/j.jtho.2017.04.014 ↗
28. 10.1016/j.carbpol.2017.09.07110.1016/j.carbpol.2017.09.071 ↗
29. 10.1016/j.biomaterials.2014.01.05010.1016/j.biomaterials.2014.01.050 ↗
30. 10.1016/j.carbpol.2013.05.07710.1016/j.carbpol.2013.05.077 ↗
31. 10.1016/j.ijbiomac.2020.12.18010.1016/j.ijbiomac.2020.12.180 ↗
32. 10.1021/bm501313t10.1021/bm501313t ↗
33. 10.1163/092050610X52272910.1163/092050610X522729 ↗
34. 10.1016/j.nano.2018.01.01510.1016/j.nano.2018.01.015 ↗
35. 10.1021/bm050747n10.1021/bm050747n ↗
36. 10.1158/0008-5472.CAN-11-095010.1158/0008-5472.CAN-11-0950 ↗
37. 10.1021/acsnano.8b0834610.1021/acsnano.8b08346 ↗
38. 10.7150/thno.1982610.7150/thno.19826 ↗
39. 10.1021/acsnano.9b0832010.1021/acsnano.9b08320 ↗
40. 10.1021/acsnano.8b0244610.1021/acsnano.8b02446 ↗
41. 10.1002/anie.20110126610.1002/anie.201101266 ↗
42. 10.1038/nrc323910.1038/nrc3239 ↗
43. 10.1038/nnano.2017.6910.1038/nnano.2017.69 ↗
44. 10.1038/nri77810.1038/nri778 ↗
45. 10.1016/j.carbpol.2017.09.07110.1016/j.carbpol.2017.09.071 ↗
46. 10.1038/s41467-021-25393-x10.1038/s41467-021-25393-x ↗